The Biomarkers, Prevention and Interventions for HIV-associated Malignancies and NCDs (BPIN) Core provides assays and data instruments to enable studies of HIV-associated malignancies.<\/p>\n
Cancer has become the leading cause of death among persons with HIV infection worldwide. Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer were recognized as AIDS-Defining Malignancies (ADM<\/strong>) early in the epidemic. In the setting of broadly available ART, cancer now impacts persons living with HIV both at the time of diagnosis and as a consequence of long-term HIV infection. In addition to ADM, people living with HIV are at increased risk of a range of cancers, including lung cancer, anal cancer, Hodgkin lymphoma, liver cancer, and head and neck cancer. Importantly, comorbid HIV infection is associated with more than a two-fold increased risk of death among persons with cancer compared with persons of the same age, sex, and stage of cancer without HIV infection. Despite more than three decades of recognizing an association between HIV and cancer, significant differences remain in our knowledge about the etiology, natural history and treatment of HIV-associated malignancies (HIVAM<\/strong>). Immunotherapeutic approaches to treating cancer in the setting of HIV are emerging as important options. To address unanswered question in the field of HIV and cancer, we are proactively continuing to foster and strengthen research in our local and global HIV communities through these specific aims:<\/p>\n\n
\n